Zhou Chengzhi
11
3
4
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Role: lead
Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine
Role: lead
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
Role: lead
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
Role: lead
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
Role: lead
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer
Role: lead
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Role: lead
Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
Role: lead
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Role: lead
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC
Role: lead
Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma
Role: lead
All 11 trials loaded